Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Basal cell carcinoma (BCC) is an epithelial tumour of the skin. It seldom metastasizes, but has the potential for local invasion and destruction. It usually occurs as one or several small pearly ...

While breast cancer is rare in men, the disease can affect men too. Men can also have breast lumps and should get a prompt medical evaluation for any lump or change in the appearance of their chest or ...

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Libtayo was approved in 2018 for advanced cutaneous squamous cell carcinoma, and since then has also been cleared for basal cell carcinoma and most recently first-line non-small cell lung cancer ...

Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced CSCC, ...